AKROライブシグナル | Getagraph.comで利益を最大化

買う 107821 min ago

@ $22.13

発行日: 15 2月 2024 @ 04:43

リターン: -10.21%

前回のシグナル: 2月 14 - 05:49

前回のシグナル: 売る

リターン: 7.64 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:41):

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health...

Stats
本日の出来高	96 828.00
平均出来高	1.40M
時価総額	1.37B
EPS	$0 ( 2024-03-15 )
次の収益日	( $-0.860 ) 2024-05-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.88
ATR14	$0.0310 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Young Jonathan	Sell	4 600	Common Stock
2024-04-01	Young Jonathan	Sell	400	Common Stoek
2024-03-13	Yale Catriona	Sell	723	Common Stock
2024-03-13	White William Richard	Sell	724	Common Stock
2024-03-13	Cheng Andrew	Sell	1 969	Common Stock

INSIDER POWER
52.13
Last 100 transactions
Buy: 2 061 541 \| Sell: 638 251

ボリューム相関

長: -0.11 (neutral)

短: -0.45 (neutral)

Signal:(71.534) Neutral

Akero Therapeutics Inc 相関

10 最も正の相関
AZYO	0.936
GNSS	0.933
VRAR	0.929
UBOH	0.929
NVCT	0.922
CULL	0.919
VERA	0.919
JRJC	0.918
EDSA	0.917
BRQS	0.91

10 最も負の相関
RXDX	-0.979
FLMN	-0.968
ZYNE	-0.962
RESN	-0.962
ZGNX	-0.959
CYT	-0.958
ADMS	-0.946
RETA	-0.946
ORTX	-0.938
XLRN	-0.931

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Akero Therapeutics Inc 相関 - 通貨/商品

-0.28
( neutral )

0.13
( neutral )

0.00
( neutral )

0.07
( neutral )

0.84
( strong )

0.17
( neutral )

Akero Therapeutics Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-29 000.00 (0.00 %)
EPS:	$-2.89

FY	2023
収益:	$0
総利益:	$-29 000.00 (0.00 %)
EPS:	$-2.89

FY	2022
収益:	$0
総利益:	$-260 000 (0.00 %)
EPS:	$-2.79

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-2.89

Financial Reports:

No articles found.

Akero Therapeutics Inc

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.